体外循环与VA-ECMO诱导的免疫功能障碍:共同特征与差异,一篇叙述性综述
本叙述性综述比较体外循环(CPB)与静脉-动脉体外膜肺氧合(VA-ECMO)诱导的免疫功能障碍。两种技术血液接触管路表面后迅速激活激肽系统、补体系统与凝血级联,释放促炎介质;缺血再灌注损伤与损伤相关分子模式释放进一步加剧炎症反应。细胞层面涉及血小板、中性粒细胞、单核细胞、树突状细胞、B和T淋巴细胞及髓源性抑制细胞的表型与功能改变,共同导致免疫麻痹。减轻免疫功能障碍的策略包括减轻CPB/ECMO期间炎症反应与增强免疫功能,如非体外循环手术、糖皮质激素、补体抑制剂、去白细胞滤器、CPB期间机械通气及精氨酸补充等,临床试验中显示不同程度的效果。作者认为针对免疫功能障碍的靶向干预对改善心脏外科与重症患者预后至关重要,未来研究应优化这些策略并开发新方法。
要点
- ECMO患者院内感染发生率高于接受CPB的患者,二者免疫功能障碍差异可能解释这一现象。
- 血液接触管路表面后迅速激活激肽系统、补体系统与凝血级联,释放促炎介质。
- 缺血再灌注损伤与损伤相关分子模式释放进一步加剧炎症反应。
- 血小板、中性粒细胞、单核细胞、树突状细胞、B和T淋巴细胞及髓源性抑制细胞均发生表型与功能改变,参与免疫麻痹。
- 非体外循环手术、糖皮质激素、补体抑制剂、去白细胞滤器、CPB期间机械通气及精氨酸补充等策略在临床试验中显示不同程度的效果。
适用人群与场景
- 接受体外循环(CPB)心脏手术的患者与接受静脉-动脉体外膜肺氧合(VA-ECMO)的重症患者。
处置流程与药物剂量
- 减轻CPB/ECMO期间炎症反应的策略包括非体外循环手术、糖皮质激素、补体抑制剂、去白细胞滤器及CPB期间机械通气,临床试验中显示不同程度的效果。
- 增强免疫功能的策略包括免疫营养,尤其是精氨酸补充,探索结果不一。
研究设计与关键结果
- 叙述性综述:CPB与VA-ECMO的免疫反应均涉及体液与细胞成分,血液接触管路表面后迅速激活激肽系统、补体系统与凝血级联,释放促炎介质。
- 缺血再灌注损伤与损伤相关分子模式释放进一步加剧炎症反应。
- 细胞反应涉及血小板、中性粒细胞、单核细胞、树突状细胞、B和T淋巴细胞及髓源性抑制细胞,均发生表型与功能改变,参与免疫麻痹。
- ECMO患者院内感染发生率高于接受CPB的患者,二者免疫功能障碍的差异可能解释这一现象。
证据类型、等级与局限
- 证据类型:叙述性综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,针对CPB与ECMO诱导的免疫功能障碍进行靶向干预,对改善心脏外科与重症监护患者的预后至关重要。
- 作者认为,未来研究应聚焦于优化这些策略并开发新方法,以更好地管理接受CPB与ECMO患者的免疫反应。
指南或共识出处
- Crit Care 发表的叙述性综述《Cardiopulmonary bypass and VA-ECMO induced immune dysfunction: common features and differences, a narrative review》。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Cardiopulmonary bypass (CPB) and veno-arterial extracorporeal membrane oxygenation are critical tools in contemporary cardiac surgery and intensive care, respectively. While these techniques share similar components, their application contexts differ, leading to distinct immune dysfunctions which could explain the higher incidence of nosocomial infections among ECMO patients compared to those undergoing CPB. This review explores the immune modifications induced by these techniques, comparing their similarities and differences, and discussing potential treatments to restore immune function and prevent infections. The immune response to CPB and ECMO involves both humoral and cellular components. The kinin system, complement system, and coagulation cascade are rapidly activated upon blood contact with the circuit surfaces, leading to the release of pro-inflammatory mediators. Ischemia-reperfusion injury and the release of damage-associated molecular patterns further exacerbate the inflammatory response. Cellular responses involve platelets, neutrophils, monocytes, dendritic cells, B and T lymphocytes, and myeloid-derived suppressor cells, all of which undergo phenotypic and functional alterations, contributing to immunoparesis. Strategies to mitigate immune dysfunctions include reducing the inflammatory response during CPB/ECMO and enhancing immune functions. Approaches such as off-pump surgery, corticosteroids, complement inhibitors, leukocyte-depleting filters, and mechanical ventilation during CPB have shown varying degrees of success in clinical trials. Immunonutrition, particularly arginine supplementation, has also been explored with mixed results. These strategies aim to balance the inflammatory response and support immune function, potentially reducing infection rates and improving outcomes. In conclusion, both CPB and ECMO trigger significant immune alterations that increase susceptibility to nosocomial infections. Addressing these immune dysfunctions through targeted interventions is essential to improving patient outcomes in cardiac surgery and critical care settings. Future research should focus on refining these strategies and developing new approaches to better manage the immune response in patients undergoing CPB and ECMO.
参考来源
- Lesouhaitier M, Belicard F, Tadié JM, et al. Cardiopulmonary bypass and VA-ECMO induced immune dysfunction: common features and differences, a narrative review. Crit Care. 2024. PMID: 39256830. doi:10.1186/s13054-024-05058-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。